We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Novel Cardiovascular Biomarker Secretoneurin Implicated in Arrhythmogenesis

By LabMedica International staff writers
Posted on 21 Oct 2021
Print article
Image: Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is caused by a build-up of fatty deposits and fibrous tissue on the right ventricle, the chamber of the heart that pumps blood into the lungs (Photo courtesy of National Heart Foundation of Australia)
Image: Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is caused by a build-up of fatty deposits and fibrous tissue on the right ventricle, the chamber of the heart that pumps blood into the lungs (Photo courtesy of National Heart Foundation of Australia)
Secretoneurin is a 33-amino acid peptide derived from neuroendocrine and myocardial tissue that belongs to the granin protein family. Secretoneurin may play a role in regulating processes in the myocardium, including cardiomyocyte Ca2+ handling, and has been implicated in arrhythmogenesis.

Those affected by arrhythmogenic cardiomyopathy may not have any symptoms at all despite having significant abnormalities in the structure of their hearts. If symptoms do occur, the initial presentation is often due to abnormal heart rhythms (arrhythmias) which in arrhythmogenic cardiomyopathy may take the form of palpitations, or blackouts.

An international team of medical scientists led by those at the Haukeland University Hospital (Bergen, Norway) included 30 healthy volunteers in a study that examined the within subject variation (CVI), between subject variation (CVG), reference change values (RCV) and index of individuality (II) of secretoneurin. Inclusion criteria were subjects 18-75 years old who reported being generally healthy, with no history of diabetes, cardiovascular disease, renal disease, chronic lung disease or cancer. The median age of the participants was 36 years and 53% were female. Secretoneurin was measured in duplicate using an ELISA (CardiNor AS, Oslo, Norway).

The investigators reported that non-fasting glucose, eGFR (CKD-EPI), cardiac troponin T (cTnT), and brain natriuretic peptide (NT-proBNP) concentrations were within the normal range for the volunteers. Median secretoneurin concentrations for females were 35 pmol/L and for males 33 pmol/L, (P-value < 0.001). CVI and CVG were 9.8% (CI 8.7% - 11.0%) and 20.0 (CI 15.4% - 28.0%), respectively. RCV were 38.7% (CI 35.5% to 42.7%) and -27.9 (CI -29.9 to -26.2) and the II were 0.60 (CI 0.42 -0.78). No gender differences were found.

The authors concluded that this study is the first to report biological variation, RCV, II and analytical quality specifications for secretoneurin. Overall low values were found indicating that secretoneurin has characteristics suitable for a biomarker that could be useful for diagnosing and monitoring disease. The study was published on October 6, 2021 in the journal Clinical Biochemistry.

Related Links:
Haukeland University Hospital
CardiNor AS

Gold Supplier
SARS-CoV-2 qRT-PCR IVD Reagent Kit
Gold Supplier
SARS-CoV-2 (ORF1a, N, RdRp) Real-Time RT-PCR Test
DiaPlexQ SARS-CoV-2 (ORF1a, N, RdRp)
Automatic Nucleic Acid Purification System
GenePure Pro
Live Cell Analysis System
BioTek BioSpa

Print article
IIR Middle East


Molecular Diagnostics

view channel

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more


view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.